LYS

National Organization for Rare Disorders Announces More Than $100,000 in Grant Funding Available for Rare Disease Research

Retrieved on: 
Tuesday, September 19, 2023
LYS, NORD, Syndrome, National Organization for Rare Disorders, NIH Intramural Research Program, Clan, Arteriovenous malformation, AVM, MMIHS, Rare, FDA, NIH, Pharmaceutical industry

DANBURY, Conn., Sept. 19, 2023 /PRNewswire/ -- The National Organization for Rare Disorders (NORD®) announced three new grant funding opportunities related to the following rare diseases: Arteriovenous Malformation (AVM), Levy-Yeboa Syndrome (LYS), and Megacystis Microcolon Intestinal Hypoperistalsis Syndrome (MMIHS).  

Key Points: 
  • The National Organization for Rare Disorders (NORD) announces three new research opportunities for AVM, LYS, and MMIHS.
  • NORD's Research Grants Program provides seed-money grants to qualified investigators for scientific and clinical research into diseases for which there are few other sources of funding.
  • With funding by the Maxwell Family, NORD is accepting applications for one grant of up to $40,000 US, for scientific and/or clinical research studies related to Levy-Yeboa syndrome (LYS).
  • To learn more or submit to the 2023 NORD Research Grants Cycle, visit rarediseases.org/advancing-research/request-for-proposals/

Lysogene Announces the Extension of Deadline for the Submission of Offers

Retrieved on: 
Thursday, February 16, 2023
Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, LYS, CNS, Interest, Central nervous system, Pharmaceutical industry, Real estate, Medical device

Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announces that, upon decision of the judicial administrator, the deadline for submitting offers has been extended from February 15, 2023 to March 15, 2023 at 12:00 (noon).

Key Points: 
  • Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announces that, upon decision of the judicial administrator, the deadline for submitting offers has been extended from February 15, 2023 to March 15, 2023 at 12:00 (noon).
  • Interested candidates are invited to contact:

Lysogene: Conversion of the Safeguard Proceedings Into Reorganization Proceedings

Retrieved on: 
Wednesday, January 25, 2023
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, LYS, CNS, Interest, Central nervous system, Commercial Court, Hearing

Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announces the conversion of the safeguard proceedings which has been in place since December 13, 2022 into reorganization proceedings.

Key Points: 
  • Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announces the conversion of the safeguard proceedings which has been in place since December 13, 2022 into reorganization proceedings.
  • As announced on January 6, 2023, in the absence of a solution to strengthen its financial situation and secure its cash runway during the safeguard proceedings, Lysogene together with the judicial administrator, filed a request with the Commercial Court of Nanterre for the conversion of the safeguard proceedings into reorganization proceedings.
  • This request was examined and approved by the Commercial Court of Nanterre at the hearing of January 24, 2023.
  • Interested candidates are invited to contact:

Lysogene: Launch of a Process to Find Buyers or Investors and Request for Conversion of Safeguard Proceedings Into Reorganization Proceedings

Retrieved on: 
Friday, January 6, 2023
Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, LYS, Interest, Central nervous system, Commercial Court, CNS

The Commercial Court of Nanterre will rule on this request in the coming days.

Key Points: 
  • The Commercial Court of Nanterre will rule on this request in the coming days.
  • This request for conversion is motivated by the fact that safeguard proceedings did not lead to the identification of a solution to strengthen Lysogene's financial situation and to secure its cash runway.
  • The conversion of safeguard proceedings into reorganization proceedings will allow Lysogene to further investigate solutions for the continuation of its activities and to conduct a search for buyers or investors.
  • In this context, a bidding process for the purpose of finding buyers or investors will be published today.

Lysogene Provides Updates and Topline Results from Phase 2/3 AAVance Gene Therapy Clinical Study

Retrieved on: 
Tuesday, November 29, 2022
Health, Neurology, Genetics, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, LYS, MPS, Central nervous system, CNS, Medical device, Pharmaceutical industry

Lysogene (FR0013233475 LYS) (Paris:LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, today announced topline results from the Phase 2/3 AAVance study evaluating LYS-SAF302, an investigational gene therapy for the treatment of MPS IIIA.

Key Points: 
  • Lysogene (FR0013233475 LYS) (Paris:LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, today announced topline results from the Phase 2/3 AAVance study evaluating LYS-SAF302, an investigational gene therapy for the treatment of MPS IIIA.
  • The current results of the AAVance study delineate the patient population that would benefit from treatment with LYS-SAF302.
  • The AAVance Phase 2/3 clinical study is an open-label, single-arm, multicenter study of LYS-SAF302 for the treatment of MPS IIIA.
  • Lysogene is a gene therapy Company focused on the treatment of orphan diseases of the central nervous system (CNS).

Lysogene Provides Updates and Topline Results from Phase 2/3 AAVance Gene Therapy Clinical Study

Retrieved on: 
Friday, November 18, 2022
Health, Neurology, Genetics, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Central nervous system, CNS, LYS, MPS, Medical device, Pharmaceutical industry

Lysogene (FR0013233475 LYS)(Paris:LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, today announced topline results from the Phase 2/3 AAVance study evaluating LYS-SAF302, an investigational gene therapy for the treatment of MPS IIIA.

Key Points: 
  • Lysogene (FR0013233475 LYS)(Paris:LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, today announced topline results from the Phase 2/3 AAVance study evaluating LYS-SAF302, an investigational gene therapy for the treatment of MPS IIIA.
  • The current results of the AAVance study delineate the patient population that would benefit from treatment with LYS-SAF302.
  • The AAVance Phase 2/3 clinical study is an open-label, single-arm, multicenter study of LYS-SAF302 for the treatment of MPS IIIA.
  • Lysogene is a gene therapy Company focused on the treatment of orphan diseases of the central nervous system (CNS).

Lysogene to Provide Updates and Topline Results from Phase 2/3 AAVance Gene Therapy Clinical Study and Host Webcast on Wednesday, November 23, 2022

Retrieved on: 
Friday, November 18, 2022
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, AAV, Parkinson, LYS, Clinical trial, Autism, Adaptive clinical trial, CNS, GBA1, MPS, Parkinson's disease, Central nervous system, GM1, Financial Services and Markets Authority (Belgium), CET, Fragile X syndrome, Weizmann Institute of Science, Webcast, Yeda, Pharmaceutical industry

Lysogene (FR0013233475 LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, today announced that it will host a live webcast on Wednesday, November 23, 2022 at 1:30 pm CET to provide updates and topline results from the Phase 2/3 AAVance study evaluating LYS-SAF302, an investigational gene therapy for the treatment of MPS IIIA.

Key Points: 
  • Lysogene (FR0013233475 LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, today announced that it will host a live webcast on Wednesday, November 23, 2022 at 1:30 pm CET to provide updates and topline results from the Phase 2/3 AAVance study evaluating LYS-SAF302, an investigational gene therapy for the treatment of MPS IIIA.
  • Lysogene is a gene therapy Company focused on the treatment of orphan diseases of the central nervous system (CNS).
  • Lysogene is also developing an innovative AAV gene therapy approach for the treatment of Fragile X syndrome, a genetic disease related to autism.
  • This press release may contain certain forward-looking statements, especially on the Companys progress of its clinical trials and cash runway.

Lysogene Provides Additional Update on AAVance Phase 2/3 Gene Therapy Clinical Trial with LYS-SAF302 in children with MPS IIIA

Retrieved on: 
Thursday, July 7, 2022
Health, Genetics, Science, Research, Clinical Trials, NFL, Nerve, Mutation, Academic Model Providing Access to Healthcare (AMPATH), Patient, Lists of diseases, HS, Cerebrospinal fluid, Tissue, Brain, CHOC, Phenotype, Adaptive clinical trial, AAV, CNS, CSF, Central nervous system, Company, Spinal cord, Disease, MPS, Autism, SGSH, DA, GM1, Weizmann Institute of Science, Serum, Infant, Clinical trial, Parkinson, Yeda, Child, CA, LYS, Parkinson's disease, Foundation, SD, Fragile X syndrome, Language, Database, Competition and Markets Authority, GBA1, Oligosaccharide, Observation, Forward-looking statement, Conference, Sanfilippo, Medical device, Pharmaceutical industry, Lysogenic cycle

Lysogene (Paris:LYS)(FR0013233475 LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, today communicates additional preliminary data from the AAVance Phase 2/3 gene therapy trial in MPS IIIA (NCT03612869).

Key Points: 
  • Lysogene (Paris:LYS)(FR0013233475 LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, today communicates additional preliminary data from the AAVance Phase 2/3 gene therapy trial in MPS IIIA (NCT03612869).
  • Lysogene is a gene therapy Company focused on the treatment of orphan diseases of the central nervous system (CNS).
  • A phase 2/3 clinical trial in MPS IIIA is ongoing.
  • Lysogene is also developing an innovative AAV gene therapy approach for the treatment of Fragile X syndrome, a genetic disease related to autism.

FounderMade Announces October 2022 BeautyMade Show

Retrieved on: 
Tuesday, May 24, 2022
Bobbi Brown, VP, Chanel, Beauty, Acceleration, Clearco, West Virginia, Show, LYS, Founder CEO, INXS: Live at Barker Hangar, Partnership, NIV, Sephora, ULTA, Ecosystem, B2B, Klarna, Founder, Lime Crime, Target, Skin care, CEO, Cosmetics, Toy, Anthropologie, Porsche

NEW YORK, May 24, 2022 /PRNewswire/ -- Brand discovery platform FounderMade and B2B media powerhouse Tarsus are pleased to announce the launch of BeautyMade: The Show for High Growth Beauty Innovators.  Scheduled to take place on Thursday, October 13, 2022, at The Barker Hangar (3021 Airport Ave) in Santa Monica, California, BeautyMade will host the most influential executives in beauty retail, investment & media, while promising to showcase the world's most creative and emerging beauty brands.

Key Points: 
  • FounderMade is partnering with The Este Lauder Companies' New Incubation Ventures (NIV) group.
  • By leveraging the BeautyMade platform, NIV is seeking to create, fund, and support emerging luxury and prestige beauty brands with innovative products and concepts to shape the next generation of beauty.
  • Noting that beauty sales have continued to grow, Meghan Asha, CEO of FounderMade believes that even the most successful industry titans need fresh ideas & approaches in order to keep up.
  • For more information about FounderMade or to register to attend BeautyMade, please visit www.foundermade.com .

Lysogene Provides Clinical Update on AAVance Phase 2/3 Clinical Trial with Gene Therapy LYS-SAF302 for the Treatment of MPS IIIA at the 25th Annual ASGCT Meeting

Retrieved on: 
Wednesday, May 18, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Other Health, N-sulfoglucosamine sulfohydrolase, Company, White matter, Sanfilippo, GM1, Patient, GBA1, Language, Weizmann Institute of Science, LYS, Clinical trial, Society, Autism, Fragile X syndrome, Gene, Observational study, SGSH, CNS, MPS, Lists of animated television series, Brain, AAV, Lists of diseases, Parkinson, Forward-looking statement, Adaptive clinical trial, Central nervous system, Financial Services and Markets Authority (Belgium), Parkinson's disease, Yeda, Cell, DA, CEO, Pharmaceutical industry, Q3

Lysogene (FR0013233475 LYS), a phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, provided updated clinical data from the ongoing AAVance phase 2/3 clinical trial with the investigational gene therapy LYS-SAF302 for the treatment of MPS IIIA (NCT03612869) during the 25th Annual Meeting of the ASGCT (American Society for Gene & Cell Therapy) in Washington, DC.

Key Points: 
  • Lysogene (FR0013233475 LYS), a phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, provided updated clinical data from the ongoing AAVance phase 2/3 clinical trial with the investigational gene therapy LYS-SAF302 for the treatment of MPS IIIA (NCT03612869) during the 25th Annual Meeting of the ASGCT (American Society for Gene & Cell Therapy) in Washington, DC.
  • These results, which suggest that younger patients are more responsive to the gene therapy treatment, need to be corroborated and confirmed by the final statistical analyses.
  • Lysogene is a gene therapy Company focused on the treatment of orphan diseases of the central nervous system (CNS).
  • Lysogene is also developing an innovative AAV gene therapy approach for the treatment of Fragile X syndrome, a genetic disease related to autism.